American Healthcare REIT IPO Could Be a Risky Bet

The recent launch of American Healthcare REIT's (AHR) initial public offering (IPO) has generated excitement in the investment community. The company is seeking up to $840 million, with plans to use the proceeds to repay debt and expand its portfolio of senior housing, care, hospital, and healthcare facilities. However, a closer look reveals that AHR's underlying assets, comprised of the merger between Griffin-American Healthcare REIT III (GAH III) and Griffin-American Healthcare REIT IV (GAH IV) and their acquisition of American Healthcare Investors (AHI), raise concerns about the IPO's long-term viability.

A History of Underperformance

Both GAH III and GAH IV have consistently underperformed industry benchmarks. GAH III, launched in 2012, has delivered an annualized total return of just 3.9%, significantly lagging behind the NAREIT Healthcare REIT Index's 8.4% return over the same period. GAH IV, launched in 2015, has fared even worse, with an annualized total return of negative 0.4%. These lackluster returns raise questions about the quality of the underlying assets and the management team's ability to generate sustainable returns.

AHI's Acquisition: A Costly Gamble

AHR's acquisition of AHI in 2023 was met with skepticism from analysts due to the high acquisition price. AHI's portfolio primarily consisted of lower-quality skilled nursing facilities (SNFs), which are facing significant challenges due to declining occupancy rates and government reimbursement cuts. The hefty price tag suggests that AHR may have overpaid for AHI, potentially saddling the new company with debt and jeopardizing future profitability.

Unveiling the Risks

While AHR's IPO prospectus touts its diversified portfolio and experienced management team, the underlying assets from GAH III, GAH IV, and AHI paint a concerning picture. Brokers recommending this IPO to their clients should carefully consider the following risks:

• Portfolio quality: The historical underperformance of GAH III and GAH IV suggests that AHR's portfolio may contain assets with below-average fundamentals, potentially impacting future returns.
• SFN exposure: AHI's SNF-heavy portfolio exposes AHR to a declining and challenging market segment, which could hinder overall growth and profitability.
• Acquisition debt: The high acquisition price of AHI could lead to significant debt burden, limiting AHR's financial flexibility and potentially impacting future dividend distributions.

Conclusion

The American Healthcare REIT IPO presents a tempting opportunity for investors seeking exposure to the healthcare real estate sector. However, the underlying assets from the merger and acquisition raise serious concerns about the company's long-term prospects. Brokers have a responsibility to carefully assess these risks before recommending the IPO to their clients. A deeper dive into the quality of AHR's assets, the impact of the SNF exposure, and the management's plan to address the debt burden is crucial before making any investment decisions.

If your broker recommended any of these or other risky investments please call Soreide Law Group at 1-888-760-6552 for a free consultation.